Medivir to acquire 100% of BioPhausia - MarketLine Financial Deals

Medivir to acquire 100% of BioPhausia

Medivir to acquire 100% of BioPhausia - MarketLine Financial Deals
Medivir to acquire 100% of BioPhausia
Published Apr 11, 2011
4 pages — Published Apr 11, 2011
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Medivir AB, a specialty pharmaceutical company focused on infectious diseases, has made an offer to acquire all shares of BioPhausia AB.

  
Source:
Document ID
MA58305_110414
Country
Country
Ticker
MVIR-B=SE
Ticker
OML=GB
Ticker
BIOP=SE
Company
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Medivir to acquire 100% of BioPhausia" Apr 11, 2011. Alacra Store. Dec 11, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Medivir-to-acquire-100-of-BioPhausia-2052-59291>
  
APA:
MarketLine Financial Deals. (2011). Medivir to acquire 100% of BioPhausia Apr 11, 2011. New York, NY: Alacra Store. Retrieved Dec 11, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Medivir-to-acquire-100-of-BioPhausia-2052-59291>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.